UBS Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-8,000
Closed -$62.4K – 10492
2025
Q4
$62.4K Hold
8,000
– – ﹤0.01% 7120
2025
Q3
$60.7K Hold
8,000
– – ﹤0.01% 7427
2025
Q2
$71.7K Hold
8,000
– – ﹤0.01% 7495
2025
Q1
$60K Hold
8,000
– – ﹤0.01% 7440
2024
Q4
$60.2K Hold
8,000
– – ﹤0.01% 7182
2024
Q3
$60.8K Hold
8,000
– – ﹤0.01% 6689
2024
Q2
$49.4K Buy
+8,000
New +$44.1K ﹤0.01% 6697
2023
Q3
– Sell
-26,800
Closed -$189K – 9456
2023
Q2
$189K Hold
26,800
– – ﹤0.01% 5519
2023
Q1
$224K Hold
26,800
– – ﹤0.01% 5300
2022
Q4
$308K Hold
26,800
– – ﹤0.01% 5101
2022
Q3
$338K Buy
+26,800
New +$345K ﹤0.01% 4678

Other funds holding BCRX

UBS Group's BCRX Position: Q3 2026 in Review

UBS Group increased its BioCryst Pharmaceuticals (BCRX) stake by 6% in Q3 2026, buying an estimated $2.89M and bringing the position to 5,385,432 shares worth $44.9M. The position accounts for 0.01% of the portfolio, ranked #1810.

UBS Group first reported a position in BCRX in Q4 2014 and has held it in 48 quarters since. The position peaked at $50.8M in Q2 2026. 334 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • UBS Group held 5,385,432 shares of BioCryst Pharmaceuticals worth $44.9M as of Q3 2026.
  • UBS Group bought 307,152 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $2.89M.
  • BioCryst Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q3 2026, its #1810 holding.
  • UBS Group first reported a position in BioCryst Pharmaceuticals in Q4 2014 and has held it in 48 quarters since.
  • UBS Group's BioCryst Pharmaceuticals position peaked at $50.8M in Q2 2026.
  • 334 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.